Product competes with ATP.
Target IC50: 7 nM, 20 nM, 1.3 nM, 700 pM, 8.5 nM, against protein kinase A , CaM kinase, myosin light chain kinase, protein kinase C, and protein kinase G, respectively
Cell permeable: yes
A potent, cell-permeable broad spectrum inhibitor of protein kinases. Inhibits CaM kinase (IC50 = 20 nM), myosin light chain kinase (IC50 = 1.3 nM), protein kinase A (IC50 = 7 nM), protein kinase C (IC50 = 0.7 nM), and protein kinase G (IC50 = 8.5 nM). Also inhibits platelet aggregation induced by collagen or ADP but has no effect on thrombin-induced platelet aggregation. Induces apoptosis in human malignant glioma cell lines. Arrests normal cells at the G1 checkpoint.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Couldwell, W.T., et al. 1994. FEBS Lett.345, 43.Nishimura, H. and Simpson, I.A. 1994. Biochem. J.302, 271.Bruno, S., et al. 1992. Cancer Res.52, 470.Kiss, Z. and Deli, E. 1992. Biochem. J.288, 853.Vitale, M.L., et al. 1992. Neuroscience51, 463.Hoffman, R. and Newland, E.S. 1991. Cancer Chemotherap. Pharmacol.28, 102.Oka, S., et al. 1986. Agric. Biol. Chem.50, 2723.
Packaged under inert gas
100 µg in Plastic ampoule
A 1 mM (100 µg/214 µl) solution of Staurosporine (Cat. No. 569397) in DMSO.
Following initial thaw, aliquot, purge with inert gas, and freeze (-70°C).
Toxicity: Irritant (B)